Cymabay therapeutics, inc. (CBAY)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Operating activities
Net loss

-13,088

-29,413

-26,282

-24,038

-23,075

-19,449

-18,563

-17,531

-17,005

-5,043

-8,234

-8,929

-5,351

-6,952

-5,879

-6,992

-6,848

-5,979

-5,865

-1,357

-2,328

-12,722

-5,961

-3,172

-10,062

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

153

150

144

140

138

66

14

13

12

9

8

9

9

8

10

6

5

5

6

5

6

5

5

5

3

Non-employee stock-based compensation expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

28

3

2

1

2

Stock-based compensation expense

1,998

2,075

2,865

2,276

2,342

1,738

1,728

1,751

1,796

982

820

1,840

1,278

676

667

571

559

613

562

607

705

272

223

75

714

Amortization of premium on marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

164

119

61

167

164

111

107

71

Net accretion and amortization of investments in marketable securities

205

328

585

780

544

587

581

499

278

152

51

-5

1

3

5

-27

-106

-76

-66

-35

-51

-54

-53

-42

-49

Non-cash interest associated with debt discount accretion

-

-

-

-

-

0

0

56

92

98

107

112

120

124

123

116

113

-

-

-

-

-

-

-

-

Change in fair value of warrant liability

-

-

-

-

-

-10

-1,031

87

4,654

777

1,798

1,064

2,134

-32

-82

359

-320

-136

-1,083

-5,327

-4,575

4,947

255

-2,750

4,784

Changes in assets and liabilities:
Receivable from collaboration

-

-

-

-

-

0

0

0

-5,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid research and development expenses and other prepaid assets

-1,951

-

-

-

2,233

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest receivable and other current assets

-310

178

-216

244

177

85

-186

132

147

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other current assets

-

-

-

-

-

-

-

-

-

-

-

-16

12

-1

3

-130

-37

-

-

-

-

-

-

-

-

Contract receivables

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-17

17

-211

197

4

-158

58

Accrued interest receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

126

-116

63

-87

89

44

22

Prepaid expenses

-

-

-

-

-

-

-338

764

159

-160

242

-2

-241

295

45

462

-41

-883

495

-367

-628

589

-73

-401

1,512

Other assets

-

-1,101

531

-392

-1,158

917

0

383

346

-

-

-

-

-

-

-

-

500

-227

171

42

-38

-408

232

211

Accounts payable

-1,290

1,009

-1,388

472

437

344

293

-702

727

227

-17

5

197

-36

-337

-505

769

301

-1,014

194

-558

1,038

-215

193

372

Accrued restructuring charges

-1,476

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued liabilities

-3,061

-4,032

3,221

582

-440

205

2,054

4,972

-781

1,873

286

40

-812

1,396

61

160

-602

-675

853

166

-390

-602

1,214

447

830

Accrued interest payable

-

-

-

-

-

0

0

-37

-6

-6

-6

-5

-6

-

-

-

-

-

-

-

-

27

28

26

26

Other liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2

2

1

3

4

3

3

Net cash used in operating activities

-14,700

-28,100

-23,200

-24,206

-22,394

-19,595

-16,077

-12,823

-6,441

-6,072

-5,466

-5,891

-2,203

-5,402

-5,741

-6,070

-6,140

-5,196

-6,660

-5,309

-6,159

-7,472

-3,892

-4,739

-5,011

Investing activities
Purchases of property and equipment

-

26

20

91

178

469

14

0

46

-

-

-

-

-

-

-

-

-

-

-

0

0

10

61

32

Purchases of marketable securities

65,503

44,713

24,902

130,381

90,897

26,960

63,497

60,982

124,943

9,444

79,119

698

9,124

3,602

1,600

16,704

1,000

1,016

28,397

6,758

6,617

-

-

-

-

Proceeds from maturities of marketable securities

112,136

54,000

63,430

57,400

78,051

54,200

75,118

58,148

35,334

14,569

7,215

3,200

5,900

13,420

2,000

14,025

20,631

7,227

3,450

13,312

7,716

5,450

2,818

1,649

582

Proceeds from sale of marketable securities

-

-

-

-

3,980

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) investing activities

46,633

9,261

38,508

-73,072

-9,044

26,771

11,607

-2,834

-89,655

5,098

-71,904

2,502

-3,224

9,818

395

-2,716

19,631

6,211

-24,947

6,554

1,099

2,898

-10,782

-9,604

550

Financing activities
Proceeds from issuance of common stock, net of issuance costs

-

0

0

-174

107,920

0

0

0

135,520

-151

91,223

0

9,364

-

-

-

-

0

21,112

0

4,263

0

23,028

0

2,402

Proceeds from issuance of common stock pursuant to equity award plans

-

282

0

7

97

24

26

245

3,276

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock upon exercise of warrants

-

-

-

-

-

50

1,513

381

656

-

-

-

-

-

-

-

-

0

0

0

426

-

-

-

-

Repayment of facility loan principal

-

-

-

-

-

0

0

5,698

829

810

793

775

759

-

-

-

-

0

3,998

384

374

-

-

-

-

Cash provided by financing activities

-

282

0

-167

108,017

24

1,539

-5,198

138,623

1,019

90,870

-775

8,605

-

-

-

-

0

26,596

-384

4,315

-196

23,028

3

2,402

Net increase in cash and cash equivalents

31,925

-18,593

15,381

-97,493

76,579

7,200

-2,931

-20,855

42,527

45

13,500

-4,164

3,178

3,674

-5,590

-8,786

13,491

1,015

-5,011

861

-745

-4,770

8,354

-14,340

-2,059

Supplemental disclosure
Cash paid for amounts included in the measurement of lease liabilities

161

158

157

156

157

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash paid for interest

-

-

-

-

-

0

0

108

123

-

-

-

192

-

-

-

-

-

-

-

-

107

109

110

109

Supplemental non-cash investing and financing activities
Accrued financing costs

-

-

-

-

174

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Fixed assets in accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

28

Issuance of common stock warrants to lenders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

443

Issuance of common stock upon warrant exercises

-

-

-

-

-

0

4,179

2,103

3,097

-

-

-

-

-

-

-

-

-

-

-

-

117

377

0

55

Noncash issuance costs incurred in common stock financing

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

453